{"id":"matching-placebo-for-selinexor","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"A matching placebo is an inert formulation designed to be indistinguishable from the active drug (selinexor) in appearance, taste, and administration route. It is used in randomized controlled trials to serve as a control arm and assess the true efficacy of selinexor by accounting for placebo effects. The actual mechanism of action belongs to selinexor, which is a selective inhibitor of nuclear export (SINE) that blocks XPO1/CRM1.","oneSentence":"This is a matching placebo control used in clinical trials for selinexor, not an active drug.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:14.143Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05611931","phase":"PHASE3","title":"Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2023-04-18","conditions":"Endometrial Cancer","enrollment":276},{"nctId":"NCT04442022","phase":"PHASE2, PHASE3","title":"A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-09-03","conditions":"Relapsed/Refractory Diffuse Large B-cell Lymphoma","enrollment":501},{"nctId":"NCT03555422","phase":"PHASE3","title":"Maintenance with Selinexor/Placebo After Combination Chemotherapy in Participants with Endometrial Cancer [SIENDO]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2018-01-05","conditions":"Endometrial Cancer","enrollment":263},{"nctId":"NCT04349098","phase":"PHASE2","title":"Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-04-17","conditions":"Coronavirus Infection","enrollment":190}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Matching placebo for selinexor","genericName":"Matching placebo for selinexor","companyName":"Karyopharm Therapeutics Inc","companyId":"karyopharm-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}